These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 35961703)

  • 1. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
    Ko S; Kim M; Molina L; Sirica AE; Monga SP
    Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
    Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
    J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma.
    Zhang Y; Xu H; Cui G; Liang B; Chen X; Ko S; Affo S; Song X; Liao Y; Feng J; Wang P; Wang H; Xu M; Wang J; Pes GM; Ribback S; Zeng Y; Singhi A; Schwabe RF; Monga SP; Evert M; Tang L; Calvisi DF; Chen X
    Gastroenterology; 2022 Aug; 163(2):481-494. PubMed ID: 35489428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NOTCH-YAP1/TEAD-DNMT1 Axis Drives Hepatocyte Reprogramming Into Intrahepatic Cholangiocarcinoma.
    Hu S; Molina L; Tao J; Liu S; Hassan M; Singh S; Poddar M; Bell A; Sia D; Oertel M; Raeman R; Nejak-Bowen K; Singhi A; Luo J; Monga SP; Ko S
    Gastroenterology; 2022 Aug; 163(2):449-465. PubMed ID: 35550144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma.
    Tóth M; Wehling L; Thiess L; Rose F; Schmitt J; Weiler SME; Sticht C; De La Torre C; Rausch M; Albrecht T; Grabe N; Duwe L; Andersen JB; Köhler BC; Springfeld C; Mehrabi A; Kulu Y; Schirmacher P; Roessler S; Goeppert B; Breuhahn K
    BMC Cancer; 2021 Oct; 21(1):1079. PubMed ID: 34615513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice.
    Nishio M; Sugimachi K; Goto H; Wang J; Morikawa T; Miyachi Y; Takano Y; Hikasa H; Itoh T; Suzuki SO; Kurihara H; Aishima S; Leask A; Sasaki T; Nakano T; Nishina H; Nishikawa Y; Sekido Y; Nakao K; Shin-Ya K; Mimori K; Suzuki A
    Proc Natl Acad Sci U S A; 2016 Jan; 113(1):E71-80. PubMed ID: 26699479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice.
    Park J; Kim JS; Nahm JH; Kim SK; Lee DH; Lim DS
    Mol Cells; 2020 May; 43(5):491-499. PubMed ID: 32451369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.
    Tao J; Calvisi DF; Ranganathan S; Cigliano A; Zhou L; Singh S; Jiang L; Fan B; Terracciano L; Armeanu-Ebinger S; Ribback S; Dombrowski F; Evert M; Chen X; Monga SPS
    Gastroenterology; 2014 Sep; 147(3):690-701. PubMed ID: 24837480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
    Alvisi G; Termanini A; Soldani C; Portale F; Carriero R; Pilipow K; Costa G; Polidoro M; Franceschini B; Malenica I; Puccio S; Lise V; Galletti G; Zanon V; Colombo FS; De Simone G; Tufano M; Aghemo A; Di Tommaso L; Peano C; Cibella J; Iannacone M; Roychoudhuri R; Manzo T; Donadon M; Torzilli G; Kunderfranco P; Di Mitri D; Lugli E; Lleo A
    J Hepatol; 2022 Nov; 77(5):1359-1372. PubMed ID: 35738508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered Expression of Hippo Signaling Pathway Molecules in Intrahepatic Cholangiocarcinoma.
    Sugimachi K; Nishio M; Aishima S; Kuroda Y; Iguchi T; Komatsu H; Hirata H; Sakimura S; Eguchi H; Bekki Y; Takenaka K; Maehara Y; Suzuki A; Mimori K
    Oncology; 2017; 93(1):67-74. PubMed ID: 28448997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of YAP1 Signaling in Biliary Development, Repair, and Disease.
    Molina L; Nejak-Bowen K; Monga SP
    Semin Liver Dis; 2022 Feb; 42(1):17-33. PubMed ID: 35073587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
    Sia D; Villanueva A; Friedman SL; Llovet JM
    Gastroenterology; 2017 Mar; 152(4):745-761. PubMed ID: 28043904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.
    Sirica AE; Strazzabosco M; Cadamuro M
    Adv Cancer Res; 2021; 149():321-387. PubMed ID: 33579427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYC determines lineage commitment in KRAS-driven primary liver cancer development.
    D'Artista L; Moschopoulou AA; Barozzi I; Craig AJ; Seehawer M; Herrmann L; Minnich M; Kang TW; Rist E; Henning M; Klotz S; Heinzmann F; Harbig J; Sipos B; Longerich T; Eilers M; Dauch D; Zuber J; Wang XW; Zender L
    J Hepatol; 2023 Jul; 79(1):141-149. PubMed ID: 36906109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors.
    Edwards AC; Stalnecker CA; Jean Morales A; Taylor KE; Klomp JE; Klomp JA; Waters AM; Sudhakar N; Hallin J; Tang TT; Olson P; Post L; Christensen JG; Cox AD; Der CJ
    Cancer Res; 2023 Dec; 83(24):4112-4129. PubMed ID: 37934103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting YAP1/TAZ in nonsmall-cell lung carcinoma: From molecular mechanisms to precision medicine.
    Mui CW; Chan WN; Chen B; Cheung AH; Yu J; Lo KW; Ke H; Kang W; To KF
    Int J Cancer; 2023 Feb; 152(4):558-571. PubMed ID: 35983734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis.
    Liu Y; Zhuo S; Zhou Y; Ma L; Sun Z; Wu X; Wang XW; Gao B; Yang Y
    J Hepatol; 2022 Mar; 76(3):652-664. PubMed ID: 34793870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of Vein-Rich Tumor Microenvironment of Intrahepatic Cholangiocarcinoma With Tertiary Lymphoid Structures and Patient Outcome.
    Doi N; Ino Y; Fuse M; Esaki M; Shimada K; Hiraoka N
    Mod Pathol; 2024 Feb; 37(2):100401. PubMed ID: 38043787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YAP and the Hippo pathway in cholangiocarcinoma.
    Sugihara T; Isomoto H; Gores G; Smoot R
    J Gastroenterol; 2019 Jun; 54(6):485-491. PubMed ID: 30815737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma.
    Xu L; Zhang Y; Lin Z; Deng X; Ren X; Huang M; Li S; Zhou Q; Fang F; Yang Q; Zheng G; Chen Z; Wu Z; Sun X; Lin J; Shen J; Guo J; Li X; Xue T; Tan J; Lin X; Tan L; Peng H; Shen S; Peng S; Li S; Liang L; Cleary JM; Lai J; Xie Y; Kuang M
    J Hepatol; 2024 Aug; 81(2):265-277. PubMed ID: 38508240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.